Roche Acquires Telavant for $7.1 Billion, Gains Rights to Develop IBS Drug RVT-3101

RVT-3101, an antibody in phase-3 trials targeting inflammatory bowel disease, has potential for broad application in inflammation and fibrosis treatment; Roche plans collaboration with Pfizer for next-gen antibody development.

Roche will pay $7.1 billion to acquire Telavant, gaining rights to develop and market the IBS drug RVT-3101 in the US and Japan. An additional payment of $150 million will also be made for near-term milestones.
RVT-3101, developed by Telavant, targets both inflammation and fibrosis, suggesting broad applicability in multiple diseases. The drug can be administered at home and has shown safety in clinical trials.
The acquisition includes an option for Roche to enter a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody currently in phase 1 of development.
RVT-3101 is currently in the phase-3 ready stage, with strong Phase 2b data in the treatment of Ulcerative Colitis. This brings the potential for Roche to rapidly move into a global Phase 3 trial.
Patients with inflammatory bowel disease (IBD), a condition targeted by RVT-3101, number nearly 8 million worldwide, underscoring the drug's potential market reach and impact.